Prevalence, risk factors and outcomes of patients coming from the community with sepsis due to multidrug resistant bacteria.
ESBL producer Enterobacteriaceae
MRSA
Pneumonia
Pseudomonas
Septic shock
Journal
Multidisciplinary respiratory medicine
ISSN: 1828-695X
Titre abrégé: Multidiscip Respir Med
Pays: Italy
ID NLM: 101477642
Informations de publication
Date de publication:
2019
2019
Historique:
received:
13
02
2019
accepted:
29
04
2019
entrez:
18
7
2019
pubmed:
18
7
2019
medline:
18
7
2019
Statut:
epublish
Résumé
Although previous studies showed an increasing prevalence of infections due to multi-drug resistant (MDR) bacteria in the community, specific data on sepsis are lacking. We aimed to assess prevalence, risk factors and outcomes of patients with sepsis due to MDR bacteria. An observational, retrospective study was conducted on consecutive adult patients coming from the community and admitted to the Policlinico Hospital, Milan, Italy, with a diagnosis of sepsis between January 2011 and December 2015. Primary study outcome was in-hospital mortality. Among 518 patients, at least one MDR bacteria was isolated in 88 (17%). ESBL+ In light of the prevalence and impact of MDR bacteria causing sepsis in patients coming from the community, physicians should consider ESBL coverage when starting an empiric antibiotic therapy in patients with specific risk factors, especially in the presence of septic shock.
Sections du résumé
BACKGROUND
BACKGROUND
Although previous studies showed an increasing prevalence of infections due to multi-drug resistant (MDR) bacteria in the community, specific data on sepsis are lacking. We aimed to assess prevalence, risk factors and outcomes of patients with sepsis due to MDR bacteria.
METHODS
METHODS
An observational, retrospective study was conducted on consecutive adult patients coming from the community and admitted to the Policlinico Hospital, Milan, Italy, with a diagnosis of sepsis between January 2011 and December 2015. Primary study outcome was in-hospital mortality.
RESULTS
RESULTS
Among 518 patients, at least one MDR bacteria was isolated in 88 (17%). ESBL+
CONCLUSION
CONCLUSIONS
In light of the prevalence and impact of MDR bacteria causing sepsis in patients coming from the community, physicians should consider ESBL coverage when starting an empiric antibiotic therapy in patients with specific risk factors, especially in the presence of septic shock.
Identifiants
pubmed: 31312449
doi: 10.1186/s40248-019-0185-4
pii: 185
pmc: PMC6610920
doi:
Types de publication
Journal Article
Langues
eng
Pagination
23Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interests. SA and GS are Associate Editors of Multidisciplinary Respiratory Medicine.
Références
Ann Intern Med. 2002 Nov 19;137(10):791-7
pubmed: 12435215
Crit Care Med. 2003 Feb;31(2):462-7
pubmed: 12576952
Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416
pubmed: 15699079
Am J Med. 2006 Mar;119(3):275.e15-23
pubmed: 16490475
Int J Antimicrob Agents. 2007 Nov;30 Suppl 1:S88-92
pubmed: 17681455
J Antimicrob Chemother. 2008 Jan;61(1):26-38
pubmed: 17986491
Clin Microbiol Infect. 2010 Sep;16(9):1408-13
pubmed: 19845694
Antimicrob Agents Chemother. 2010 Dec;54(12):5099-104
pubmed: 20837757
J Infect. 2011 Feb;62(2):130-5
pubmed: 21195110
Diagn Microbiol Infect Dis. 2011 Apr;69(4):363-9
pubmed: 21396530
Antimicrob Agents Chemother. 2011 Jul;55(7):3485-90
pubmed: 21537020
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Clin Infect Dis. 2012 Jan 15;54(2):193-8
pubmed: 22109951
Clin Infect Dis. 2012 Feb 15;54(4):470-8
pubmed: 22109954
Future Microbiol. 2012 Oct;7(10):1173-89
pubmed: 23030423
Am J Respir Crit Care Med. 2013 Oct 15;188(8):985-95
pubmed: 23855620
N Engl J Med. 2013 Aug 29;369(9):840-51
pubmed: 23984731
Infect Control Hosp Epidemiol. 2013 Oct;34(10):1077-86
pubmed: 24018925
Virulence. 2014 Jan 1;5(1):4-11
pubmed: 24335434
BMC Infect Dis. 2014 Mar 04;14:126
pubmed: 24592979
PLoS One. 2014 Mar 18;9(3):e91713
pubmed: 24643200
Crit Care Med. 2014 Nov;42(11):2342-9
pubmed: 25072764
Crit Care. 2014 Nov 21;18(6):596
pubmed: 25412897
Ann Pharmacother. 2015 Jun;49(6):649-55
pubmed: 25795004
Infection. 2015 Jun;43(3):345-52
pubmed: 25840554
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Curr Opin Pulm Med. 2016 May;22(3):219-26
pubmed: 26960007
Dtsch Arztebl Int. 2016 Mar 11;113(10):159-66
pubmed: 27010950
Lancet Infect Dis. 2016 Dec;16(12):1364-1376
pubmed: 27593581
J Infect. 2017 Feb;74(2):107-117
pubmed: 27884733
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
J Intern Med. 1998 Nov;244(5):379-86
pubmed: 9845853